Granted Patent B2

US 8,852,573 · App. 13/370,034 · Granted Oct 7, 2014

Inventors: Mark F. Pittenger (Severna Park, MD); Stephen L. Gordon (Columbia, MD); Alastair Morgan Mackay (Towson, MD)

Assignee: Mesoblast International Sarl

Abstract

Claims (10)

1. A method of augmenting ventricular function in a patient comprising the step of: administering to the heart of a human patient in need thereof a cell suspension, wherein the cell suspension comprises adult human allogeneic mesenchymal stem cells and a pharmaceutically acceptable liquid medium, in an amount effective to augment ventricular function.

2. The method of claim 1 , wherein the human patient has a left ventricular ejection fraction of less than about 40%.

3. The method of claim 1 , wherein the adult human allogeneic mesenchymal stem cells are administered in a pharmaceutically acceptable liquid carrier.

4. The method of claim 3 , wherein the pharmaceutically acceptable carrier comprises an isotonic liquid.

5. The method of claim 4 , wherein the isotonic liquid comprises phosphate buffer saline, physiological saline, culture medium, or 5% dextrose in water.

6. The method of claim 4 , wherein the pharmaceutically acceptable carrier comprises phosphate buffer saline.

7. The method of claim 1 , wherein the adult human allogeneic mesenchymal stem cells are administered in a suspension containing about 10×10 6 to about 40×10 6 mesenchymal stem cells per ml.

8. The method of claim 7 , wherein the suspension is administered in an amount of about 20 μl to about 150 ml.

9. The method of claim 7 , wherein the suspension is administered in an amount of at least about 20 μl.

10. The method of claim 7 , wherein the suspension is administered in an amount of at least about 150 μl.

Assignments (4)

Continuity (8)